Daratumumab Improves PFS in Multiple Myeloma Daratumumab Improves PFS in Multiple Myeloma

Daratumumab added to bortezomib and dexamethasone improves progression-free survival (PFS) in patients with relapsed or refractory multiple myeloma (MM), according to results from the CASTOR trial.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news